

ADVENTRX PHARMACEUTICALS INC

Form 8-K

December 08, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported): December 7, 2005  
ADVENTRX Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)  
Delaware  
(State or other jurisdiction of incorporation)**

**001-32157** (Commission File Number) **84-1318182** (IRS Employer Identification No.)  
**6725 Mesa Ridge Road, Suite 100**  
**San Diego, California 92121**  
(Address of principal executive offices) (Zip Code)  
**(858) 552-0866**  
(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On December 7, 2005, the Company announced that it had conducted a pre-IND meeting with the US Food and Drug Administration regarding a proposed 505(b)(2) New Drug Application regulatory plan for ANX-530 (vinorelbine emulsion) and that the FDA has affirmed the Company's proposal to conduct a single bioequivalency study of ANX-530 as a marketing-enabling clinical trial.

The press release issued by the Company on December 7, 2005 with respect to this matter is included with this report as an exhibit.

**Item 9.01. Financial Statements and Exhibits.**

(99) (c) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

By: /s/ Carrie E. Carlander  
Name: Carrie E. Carlander  
Title: Chief Financial Officer, Vice  
President  
Finance, and Treasurer

December 7, 2005

---

**Table of Contents**

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release of the Company dated December 7, 2005.